Clostridium difficile and Clostridium perfringens type A are infectious agents of enteric diseases. The main virulence factors of these microorganisms include toxins A and B of C. difficile (ToxA and ToxB) and enterotoxin of C. perfringens (Cpe). In this study genetic constructions have been created for the expression of ToxA, ToxB and Cpe fragments either as individual components or as a hybrid multidomain (ToxA-ToxB-Cpe) protein. Rabbit monospecific sera raised against individual peptides reacted with the chimeric product indicating that the corresponding antigenic determinants were correctly expressed on the hybrid molecule. Furthermore, mice immunized with the fusion protein produced antibodies specific to each of the three separate components. These data suggest that the constructed three-domain molecule could be used in future studies for development of a vaccine against enteric clostridial diseases.
Introduction
Diarrheal infections represent one of the leading causes of human morbidity and mortality in the world. In a considerable number of cases they represent nosocomial infections, complicating antibiotic treatment of another disease. The predominant pathogens of such antibioticassociated intestinal diseases include anaerobic sporeforming Clostridium di⁄cile and Clostridium perfringens type A microorganisms [1^3] . Their main virulence factors, participating in the pathogenesis of diarrheal syndrome, are toxin A (ToxA) and toxin B (ToxB) of C. di⁄cile and enterotoxin (Cpe) of C. perfringens [4, 5] .
Toxins A and B of C. di⁄cile are large single-chain proteins with molecular masses of 308 kDa and 270 kDa respectively. The N-terminal part of these toxins includes a glucosyltransferase domain, which is responsible for the modi¢cation of eukaryotic Ras-related proteins. The middle part is thought to participate in translocation of the toxins inside the target eukaryotic cell, whereas the C-terminal part encompasses the receptor-binding domain [6, 7] . There is a considerable body of information documenting that the C-terminal part of C. di⁄cile toxins possesses protective activity against experimental C. di⁄cile infection and thus could be used for development of preparations suitable for prophylaxis and immunotherapy of the disease [8^10] .
Enterotoxin of C. perfringens type A is a 35-kDa protein, which is produced during sporulation of vegetative bacteria [11] . It binds speci¢c eukaryotic receptors and subsequently alters the membrane permeability of intestinal epithelial cells apparently by producing pores in the target cytoplasmic membrane [12^15]. The protective activity of Cpe has been considerably less investigated than C. di⁄cile toxins. However, available information indicates that C. perfringens enterotoxin could be a possible candidate for the development of a vaccine against Cpemediated disease [16] .
Based upon these data we decided to construct a chimeric protein composed of the C-terminal domains of C. di⁄cile toxins A and B and C. perfringens type A enterotoxin. Such a molecule could be a potential candidate for a gene-engineered vaccine against clostridial enteric infections.
Materials and methods

Bacterial strains and plasmids
Toxin-producing strains D1/11 of C. di⁄cile and E3 of C. perfringens type A were from the bacterial collection of the Gamaleya Research Institute. These strains were grown in pre-reduced brain-heart infusion (3.7%)-yeast extract (1%) broth (Difco, USA) for 2^3 days at 37 ‡C. Escherichia coli strains XL1-blue and BL21(DE3) and the expression vectors pET28a, pET28b (Novagen, USA) and pGEX-4T-3 (Amersham Biosciences, Austria) were used for cloning and the production of recombinant proteins. E. coli was maintained on Luria^Bertani (LB) agar or in LB broth supplemented with 50 Wg ml 31 kanamycin or 200 Wg ml 31 ampicillin when necessary [17] .
PCR ampli¢cation and cloning procedures
Clostridial genomic DNAs were extracted by the phenolic method [17] . Primers used for polymerase chain reaction (PCR) are shown in Table 1 . The PCR was performed under standard conditions (i.e. denaturation at 94 ‡C, annealing at 55 ‡C, and elongation at 72 ‡C) in a Sprint thermocycler (Hybaid, UK). For cloning of the genes, the PCR products were digested with the corresponding pairs of restriction endonucleases (Amersham Biosciences) and ligated into similarly digested pET28a or pET28b. E. coli XL1-blue (used for routine subcloning) and BL21(DE3) (used for production of recombinant proteins) were transformed with the resulting plasmids by electroporation using the Electroporator 2510 (Eppendorf, Germany).
For puri¢cation of recombinant proteins, the E. coli clones were grown in LB broth supplemented with kanamycin or ampicillin for 3 h on a shaker at 37 ‡C. Hyperexpression of the cloned proteins was then induced by supplementation of the culture with 0.5 mM of isopropyl-L-D-thiogalactopyranoside (IPTG, Sigma, USA) for an additional 3 h. The bacterial cells from 100 ml of culture were harvested by centrifugation at 8000Ug for 15 min, resuspended in 6 ml of 20 mM Tris^HCl-bu¡ered saline (TBS), and then lysed by ultrasonic treatment, i.e. three 20-s pulses, with 1-min intervals at high power setting (MSE, UK). Following centrifugation, the supernatant, containing soluble proteins, and the pellet, containing insoluble recombinant proteins ('inclusion bodies'), were subjected to chromatography on glutathione-Sepharose 4B or nickel-equilibrated Chelating Sepharose Fast Flow (Amersham Biosciences) respectively according to the manufacturer's instructions. Pure proteins were stored at 320 ‡C.
Immunization procedures
Rabbits and mice for animal studies were obtained from Table 1 Cloning of fragments of genes encoding toxins A and B of C. di⁄cile and enterotoxin of C. perfringens the animal facility at the Gamaleya Research Institute. For the production of hyperimmune antiserum, rabbits weighing 2^3 kg were immunized three times with 100 Wg of puri¢ed recombinant proteins (i.e. ToxA, ToxB or Cpe) in 0.5 ml of TBS at 2-week intervals without adjuvants. Ten days after the last injection, the rabbits were exsanguinated by sublethal cardiac puncture, and the resultant sera stored. For testing immunogenic activity of the fusion molecule, BALB/c mice weighing 20 g were immunized with ca. 1 Wg of the protein in 100 Wl of TBS twice with a 5-day interval. Five days after the second injection mice were lethally exsanguinated by cardiac puncture under chloroform anesthesia. Protein concentrations were determined by the Coomassie brilliant blue G250 assay (Serva, Germany), using bovine serum albumin as a standard [18] .
ELISA, electrophoresis and immunoblot analysis
For enzyme-linked immunosorbent assay (ELISA) £at-bottom wells of standard microplates (Nunc, Denmark) were coated with 10 Wg of puri¢ed proteins in 100 Wl of TBS overnight at 4 ‡C. Plates were processed sequentially with 1/100 dilutions of mouse sera and anti-mouse horseradish conjugate (NearMedic, Russia). The reaction was developed with the 3,3P,5,5P-tetramethylbenzidine color kit according to the manufacturer's instructions (NearMedic).
Following sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) [19] , immunoblot analysis was performed according to the standard procedure [20] , using 1/4000^1/6000 dilution of primary rabbit sera and anti-rabbit horseradish conjugate (NearMedic).
Statistics
Statistical analysis was performed using Student's t-test and the method of Reed and Muench [21] .
Results and discussion
By PCR ampli¢cation of the target genes and restriction^ligation procedures with the pET28a and pET28b vectors we produced several plasmids, carrying corresponding inserts^fragments of toxin genes (Table 1) . Thus, plasmids p28a-5 and p28a-2 were derivatives of vector pET28a and included sequences encoding fragments of C. di⁄cile toxin A (amino acid residues 2482^2710 of 2710 in total) and toxin B (amino acid residues 1701^2146 of 2366 in total) respectively. Plasmid p28b-14 was constructed on the basis of pET28b and carried the C. perfringens enterotoxin gene (amino acid residues 2^319 of 319 in total). Due to the engineered restriction endonuclease sites several mutations have been introduced into the termini of the corresponding genes. These resulted in changes in the predicted amino acid sequences of the recombinant proteins, i.e. W 2483 was replaced by S in ToxA, I 1702 was replaced by F and D 2145 was replaced by V in ToxB, and L 2 was replaced by N in Cpe.
Vectors of the pET28 series allow cloning of the gene of interest under T7 promoter and downstream of the sequence encoding the poly-histidine tag. Such a construction permits strong induction of the cloned gene by the lactose analog IPTG, while the poly-histidine sequence allows simple puri¢cation of the recombinant protein by nickel a⁄nity chromatography. Indeed, the production of C. di⁄cile toxin A and B fragments was considerable and routinely we get more than 1 mg of each protein in pure form from 100 ml of E. coli cultures (Fig. 1) . It should be noted that the vast majority of induced peptides were found in the insoluble fraction and should be solubilized by 6 M urea treatment before chromatography. Recombinant Cpe also produced inclusion bodies, but, in contrast to C. di⁄cile toxin fragments, it remained insoluble in the presence of urea or even in 1% SDS solution (data not shown). Therefore, we utilized another vector, pGEX-4T-3, which allowed cloning the sequence of interest downstream of the gene of glutathione transferase. Glutathione transferase is known to be produced in E. coli in huge amounts in soluble form and therefore we expect that the fusion molecule, composed of this protein and Cpe, will be soluble as well [22] .
To produce such a construction, the nucleotide sequence encoding Cpe was re-cut from p28b-14 by EcoRI/SalI restriction endonucleases and ligated into similarly digested pGEX-4T-3. The resulting plasmid was named p4T3-68. An E. coli strain transformed with this plasmid produced large amounts (ca. 5 mg per 100 ml of culture) of soluble Cpe, which was subsequently puri¢ed using glutathioneSepharose (Fig. 1) .
Due to the fact that toxins of C. di⁄cile and enterotoxin of C. perfringens type A are major virulence factors of the corresponding infectious agents, vaccine preparations against enteric clostridial diseases should apparently include antigenic determinants of all these toxins. It could be done actually by simply mixing the antigenic preparations. However, we decided that construction of a chimeric protein composed of the three molecules could be a rational alternative.
For this purpose, genes encoding the ToxA, ToxB and Cpe fragments were PCR-ampli¢ed using primers with chosen pairs of engineered restriction endonuclease sites (Table 1) . Ampli¢ed sequences were digested by BamHI/ EcoRI, EcoRI/SacI or SacI/SalI and ligated sequentially into analogously restricted pET28a. Thus, the resulting plasmid p28a-54 contained all three coding fragments in the order ToxA-ToxB-Cpe. After transformation of E. coli BL21(DE3) with this plasmid and induction of gene expression by IPTG we observed accumulation of the recombinant protein in inclusion bodies. As with fragments of C. di⁄cile toxins, the chimeric protein could be puri¢ed on nickel-equilibrated chelating Sepharose after dissolving with 6 M urea. However, the production of fusion protein was considerably lower than that of the individual peptides and the yield of pure product did not exceed 50 Wg per 100 ml of bacterial culture. In addition, following puri¢cation we observed multiple protein bands in SDSP AGE gels, which were indicative apparently of incomplete transcription/translation processes in bacterial cells and/or proteolysis of already synthesized protein (Fig. 1) . To con¢rm that these bands originated from the expressed product but were not co-puri¢ed contaminants we similarly processed ultrasonic extracts of E. coli cells transformed with pET28a or pGEX-4T-3 plasmids. In the former case we observed a blank lane in the SDS^PAGE gel, while with E. coli (pGEX-4T-3) the only detected component was pure 28-kDa glutathione transferase (data not shown).
To test if the constructed chimeric protein contained antigens of clostridial toxins in immunogenically active form we utilized two approaches. First, we studied the reactivity of the fusion molecule with the antisera raised against individual puri¢ed peptides by Western blotting.
As shown in Fig. 2 , these rabbit antisera reacted both with the homologous peptides and with the fusion protein but were inactive toward heterologous antigens. Second, we immunized mice with the chimeric (ToxA-ToxB-Cpe) molecule and investigated the resulting sera in ELISA with individual fragments (ToxA, ToxB or Cpe) as antigens. The results of ELISA (Table 2) indicated that following immunization, antibodies speci¢c to individual fragments could be readily detected in mouse sera. These data demonstrated that the constructed fusion molecule possessed immunogenic epitopes of C. perfringens enterotoxin, toxin A and toxin B of C. di⁄cile.
Gene-engineering approaches have been widely used for production of recombinant molecules suitable for incorporation into vaccines against di¡erent diseases, including clostridial enteric infections. For example, individual C-terminal domains of toxin A or toxin B of C. di⁄cile have been used for prophylaxis of experimental C. di⁄cile-associated disease [8^10]. However, isolation of strains of di¡erent toxinotypes (e.g. ToxA þ ToxB þ or ToxA 3 ToxB þ [23] ) indicated that an e¡ective preparation for prophylaxis/immunotherapy of C. di⁄cile infection should contain antigens of both toxic molecules. On the other hand, recent data indicated that C. perfringens type A is the second (after C. di⁄cile) leading cause of antibioticassociated diarrhea and is sometimes associated with C. di⁄cile infection [2, 3] . Therefore development of pro- Table 2 Antibody response following immunization of mice with the chimeric (ToxA-ToxB-Cpe) construction tective immunity against nosocomial antibiotic-associated infectious diseases is supposed to depend on at least three proteins^toxins of C. di⁄cile and enterotoxin of C. perfringens. Based upon this information we constructed a chimeric peptide containing fragments of these three geneŝ ToxA, ToxB and Cpe^and demonstrated that this fusion molecule was e¡ective in eliciting an antibody response against each component. Future studies will show if the developed fusion protein could be used as a component of a vaccine against enteric clostridial diseases.
